{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T05:15:19Z","timestamp":1783401319305,"version":"3.54.6"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s10067-026-08208-6","type":"journal-article","created":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T14:30:39Z","timestamp":1780669839000},"page":"4441-4447","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of Iguratimod-based therapy for the treatment of SAPHO syndrome: a prospective cohort study"],"prefix":"10.1007","volume":"45","author":[{"given":"Hongji","family":"Duan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wangna","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7206-7632","authenticated-orcid":false,"given":"Xiaoli","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,5]]},"reference":[{"issue":"3","key":"8208_CR1","first-page":"187","volume":"54","author":"AM Chamot","year":"1987","unstructured":"Chamot AM, Benhamou CL, Kahn MF, Beraneck L, Kaplan G, Prost A (1987) [Acne-pustulosis-hyperostosis-osteitis syndrome. Results of a national survey. 85 cases]. Rev Rhum Mal Osteoartic 54(3):187\u201396","journal-title":"Rev Rhum Mal Osteoartic"},{"issue":"5","key":"8208_CR2","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1093\/rheumatology\/keh149","volume":"43","author":"H Amital","year":"2004","unstructured":"Amital H, Applbaum YH, Aamar S, Daniel N, Rubinow A (2004) SAPHO syndrome treated with pamidronate: an open-label study of 10 patients. Rheumatology (Oxford) 43(5):658\u2013661","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"8208_CR3","first-page":"112","volume":"27","author":"M Colina","year":"2009","unstructured":"Colina M, La Corte R, Trotta F (2009) Sustained remission of SAPHO syndrome with pamidronate: a follow-up of fourteen cases and a review of the literature. Clin Exp Rheumatol 27(1):112\u20135","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"8208_CR4","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1093\/rheumatology\/kei160","volume":"45","author":"E Solau-Gervais","year":"2006","unstructured":"Solau-Gervais E, Soubrier M, Gerot I et al (2006) The usefulness of bone remodelling markers in predicting the efficacy of pamidronate treatment in SAPHO syndrome. Rheumatology (Oxford) 45(3):339\u201342","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"8208_CR5","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.3899\/jrheum.091086","volume":"37","author":"K Ben Abdelghani","year":"2010","unstructured":"Ben Abdelghani K, Dran DG, Gottenberg JE, Morel J, Sibilia J, Combe B (2010) Tumor necrosis factor-alpha blockers in SAPHO syndrome. J Rheumatol 37(8):1699\u2013704","journal-title":"J Rheumatol"},{"issue":"4","key":"8208_CR6","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1254\/jjp.67.305","volume":"67","author":"K Tanaka","year":"1995","unstructured":"Tanaka K, Kawasaki H, Kurata K, Aikawa Y, Tsukamoto Y, Inaba T (1995) T-614, a novel antirheumatic drug, inhibits both the activity and induction of cyclooxygenase-2 (COX-2) in cultured fibroblasts. Jpn J Pharmacol 67(4):305\u2013314","journal-title":"Jpn J Pharmacol"},{"issue":"9","key":"8208_CR7","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1358\/dot.2012.48.9.1855758","volume":"48","author":"HA Mucke","year":"2012","unstructured":"Mucke HA (2012) Iguratimod: a new disease-modifying antirheumatic drug. Drugs Today 48(9):577\u2013586","journal-title":"Drugs Today"},{"issue":"1","key":"8208_CR8","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s10067-023-06782-7","volume":"43","author":"H Duan","year":"2024","unstructured":"Duan H, Gao S, Zhang L, Song L, Zhai J, Deng X (2024) The clinical characteristics and prognosis of patients with SAPHO syndrome--a real-world cohort study. Clin Rheumatol 43(1):561\u2013568","journal-title":"Clin Rheumatol"},{"issue":"2","key":"8208_CR9","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/S0950-3579(94)80022-7","volume":"8","author":"MF Kahn","year":"1994","unstructured":"Kahn MF, Khan MA (1994) The SAPHO syndrome. Baillieres Clin Rheumatol 8(2):333\u2013362","journal-title":"Baillieres Clin Rheumatol"},{"issue":"1","key":"8208_CR10","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1093\/rheumatology\/kel190","volume":"46","author":"A Jansson","year":"2007","unstructured":"Jansson A, Renner ED, Ramser J et al (2007) Classification of non-bacterial osteitis: retrospective study of clinical, immunological and genetic aspects in 89 patients. Rheumatology (Oxford) 46(1):154\u201360","journal-title":"Rheumatology (Oxford)"},{"key":"8208_CR11","unstructured":"Xu D, Liu X, Lu C et al (2019) Reduction of peripheral natural killer cells in patients with SAPHO syndrome. Clin Exp Rheumatol 37(1):12\u201318"},{"key":"8208_CR12","doi-asserted-by":"crossref","unstructured":"Zhang S, Li C, Zhang S et al (2019) Serum levels of proinflammatory, anti-inflammatory cytokines, and RANKL\/OPG in synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome. Mod Rheumatol 29(3):523\u2013530","DOI":"10.1080\/14397595.2018.1469580"},{"issue":"6","key":"8208_CR13","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1023\/A:1016281608773","volume":"12","author":"N Pennanen","year":"1995","unstructured":"Pennanen N, Lapinjoki S, Urtti A, Monkkonen J (1995) Effect of liposomal and free bisphosphonates on the IL-1 beta, IL-6 and TNF alpha secretion from RAW 264 cells in vitro. Pharm Res 12(6):916\u201322","journal-title":"Pharm Res"},{"issue":"3","key":"8208_CR14","first-page":"430","volume":"30","author":"WP Maksymowych","year":"2003","unstructured":"Maksymowych WP (2003) Bisphosphonates for arthritis- -a confusing rationale. J Rheumatol 30(3):430\u20134","journal-title":"J Rheumatol"},{"issue":"1","key":"8208_CR15","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s12969-017-0216-7","volume":"15","author":"A Taddio","year":"2017","unstructured":"Taddio A, Ferrara G, Insalaco A et al (2017) Dealing with chronic non-bacterial osteomyelitis: a practical approach. Pediatr Rheumatol Online J 15(1):87","journal-title":"Pediatr Rheumatol Online J"},{"issue":"10","key":"8208_CR16","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1093\/rheumatology\/41.10.1196","volume":"41","author":"PA Courtney","year":"2002","unstructured":"Courtney PA, Hosking DJ, Fairbairn KJ, Deighton CM (2002) Treatment of SAPHO with pamidronate. Rheumatology (Oxford) 41(10):1196\u20138","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"8208_CR17","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1093\/rheumatology\/41.2.231-a","volume":"41","author":"H Marshall","year":"2002","unstructured":"Marshall H, Bromilow J, Thomas AL, Arden NK (2002) Pamidronate: a novel treatment for the SAPHO syndrome? Rheumatology (Oxford) 41(2):231\u20133","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"8208_CR18","doi-asserted-by":"publisher","first-page":"2970","DOI":"10.1002\/art.20464","volume":"50","author":"P Kopterides","year":"2004","unstructured":"Kopterides P, Pikazis D, Koufos C (2004) Successful treatment of SAPHO syndrome with zoledronic acid. Arthritis Rheum 50(9):2970\u20133","journal-title":"Arthritis Rheum"},{"key":"8208_CR19","unstructured":"Tanaka K, Shimotori T, Makino S et al (1992) Pharmacological studies of the new antiinflammatory agent 3-formylamino-7-methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-o ne. 1st communication: antiinflammatory, analgesic and other related properties. Arzneimittelforschung 42(7):935\u201344"},{"issue":"4","key":"8208_CR20","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1007\/PL00000291","volume":"51","author":"Y Aikawa","year":"2002","unstructured":"Aikawa Y, Yamamoto M, Yamamoto T, Morimoto K, Tanaka K (2002) An anti-rheumatic agent T-614 inhibits NF-kappaB activation in LPS- and TNF-alpha-stimulated THP-1 cells without interfering with IkappaBalpha degradation. Inflamm Res 51(4):188\u201394","journal-title":"Inflamm Res"},{"key":"8208_CR21","unstructured":"Kohno M, Aikawa Y, Tsubouchi Y et al (2001) Inhibitory effect of T-614 on tumor necrosis factor-alpha induced cytokine production and nuclear factor-kappaB activation in cultured human synovial cells. J Rheumatol 28(12):2591\u20132596"},{"key":"8208_CR22","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/214683","author":"Y Wei","year":"2015","unstructured":"Wei Y, Sun X, Hua M, Tan W, Wang F, Zhang M (2015) Inhibitory effect of a novel antirheumatic drug T-614 on the IL-6-induced RANKL\/OPG, IL-17, and MMP-3 expression in synovial fibroblasts from Rheumatoid Arthritis patients. Biomed Res Int. https:\/\/doi.org\/10.1155\/2015\/214683","journal-title":"Biomed Res Int"},{"key":"8208_CR23","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.intimp.2016.03.038","volume":"35","author":"K Gan","year":"2016","unstructured":"Gan K, Yang L, Xu L (2016) Iguratimod (T-614) suppresses RANKL-induced osteoclast differentiation and migration in RAW264.7 cells via NF-kappaB and MAPK pathways. Int Immunopharmacol 35:294\u2013300","journal-title":"Int Immunopharmacol"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-08208-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-026-08208-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-08208-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T04:27:01Z","timestamp":1783398421000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-026-08208-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,5]]},"references-count":23,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["8208"],"URL":"https:\/\/doi.org\/10.1007\/s10067-026-08208-6","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,5]]},"assertion":[{"value":"13 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Each patient signed an informed consent to publish.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}